Corcept Therapeutics Incorporated CORT
At closeNov 3, 2026, 5:27 PM EST
After hours · Nov 3, 5:27 PM ET
- YTD
- +135.43%
- 1 year
- +10.46%
Discussion (16)
Sign in to join the discussion
$CORT almost every drug can cause DILI. Many of the 1st line cancer treatment including the new immuno therapy can cause auto immune liver injury. This will not prevent this from getting approved for ovarian cancer treatment.
$CORT completely unwarranted drop in old known news. Limited move on ovarian cancer data
$CORT Big drop at the end of the day due to the CRL. Ovarian cancer data should take this to at least $50-60 range
$CORT over yesterdays high of 43.5 and we could see a large move today
$CORT adding for a swing. Phase 3 data. Should make its way back to the 200 day
$CORT, will get some buyers if it breaks $43 with more above $43.5
Having dealt with the FDA many times in my career of drug development, the CRL does not mean flat out rejection. Several paths may be possible: need for some post-hoc analysis with external expert opinion, some type of post approval commitment, etc.
I believe this is a heavy short.
Uh, there are a lot of cheerleaders here.
Any investors?
I know for sure no one with a brain is buying this shit.
